ONCOLOGY Vol 15 No 8 | Oncology

August 01, 2001

The finding by a California jury in mid-June that a state physician was guilty of elder abuse and neglect because the physician undermedicated a terminal bone cancer patient gave new impetus to the Conquering Pain Act, a bill that was introduced by

August 01, 2001

Written by Jimmie C. Holland, MD, and Sheldon Lewis, this book focuses on the "human effects" as opposed to the

August 01, 2001

The US Food and Drug Administration (FDA) has approved capecitabine (Xeloda), the first oral chemotherapy for the

August 01, 2001

If he needed more encouragement than the California verdict, Sen.Wyden (D-Ore) got it a week later when the National

August 01, 2001

Researchers at the University of Nebraska Medical Center/Nebraska Health System (UNMC/NHS) are investigating one of

August 01, 2001

According to phase III trial data presented at the recent meeting of the American Society of Clinical Oncology (ASCO)

August 01, 2001

Promising interim results of a double-blind placebo-controlled trial of the monoclonal antibody OvaRex in 345 patients with

August 01, 2001

Cancer patients are at high riskof potentially fatal blood clots

August 01, 2001

The combination of chemotherapy and radiation offers patients with advanced cancer of the larynx greater hope of preserving

August 01, 2001

In the United States, tobacco use is the leading cause of preventable death. Exposure to environmental tobacco smoke (ETS)

August 01, 2001

The incidence of invasive aspergillosis is increasing parallel to the intensity of immunosuppressive and myelosuppressive anticancer treatments. Successful management is linked to an understanding of the

August 01, 2001

The goal of identifying a set of pretreatment risk-stratifying factors for patients with localized prostate cancer is to be able to individualize treatment and optimize patient selection for clinical trials. Low-risk patients are most likely

August 01, 2001

Myeloproliferative disorders originate in the clonal expansion of a transformed pluripotential hematopoietic progenitor cell. This results in a group of syndromes that include polycythemia vera, essential thrombocythemia,

August 01, 2001

The goal of identifying a set of pretreatment risk-stratifying factors for patients with localized prostate cancer is to be able to individualize treatment and optimize patient selection for clinical trials. Low-risk patients are most likely

August 01, 2001

Myeloproliferative disorders originate in the clonal expansion of a transformed pluripotential hematopoietic progenitor cell. This results in a group of syndromes that include polycythemia vera, essential thrombocythemia,

August 01, 2001

Given the well-established role of angiogenesis (or new blood vessel formation) in tumor growth and metastasis, antiangiogenic therapy, a concept first proposed by Dr. Judah Folkman,[1] has become increasingly recognized as a promising

August 01, 2001

The goal of identifying a set of pretreatment risk-stratifying factors for patients with localized prostate cancer is to be able to individualize treatment and optimize patient selection for clinical trials. Low-risk patients are most likely

August 01, 2001

The incidence of invasive aspergillosis is increasing parallel to the intensity of immunosuppressive and myelosuppressive anticancer treatments. Successful management is linked to an understanding of the

August 01, 2001

Myeloproliferative disorders originate in the clonal expansion of a transformed pluripotential hematopoietic progenitor cell. This results in a group of syndromes that include polycythemia vera, essential thrombocythemia,

August 01, 2001

The incidence of invasive aspergillosis is increasing parallel to the intensity of immunosuppressive and myelosuppressive anticancer treatments. Successful management is linked to an understanding of the

August 01, 2001

The goal of identifying a set of pretreatment risk-stratifying factors for patients with localized prostate cancer is to be able to individualize treatment and optimize patient selection for clinical trials. Low-risk patients are most likely

August 01, 2001

Anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are members of the third generation of aromatase inhibitors that has now replaced aminoglutethimide (Cytadren), the progestins, and tamoxifen

August 01, 2001

Anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are members of the third generation of aromatase inhibitors that has now replaced aminoglutethimide (Cytadren), the progestins, and tamoxifen

August 01, 2001

Anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are members of the third generation of aromatase inhibitors that has now replaced aminoglutethimide (Cytadren), the progestins, and tamoxifen